Association of thrombotic microangiopathy with atezolizumab therapy in cancer patients

Currently, the landscape of the Food and Drug Administration–approved immune checkpoint inhibitors (CPIs) for cancer therapy include atezolizumab, avelumab, cemiplimab, durvalumab, ipilimumab, nivolumab, and pembrolizumab. These agents cause a raised immune response leading to immune-related adverse events (irAEs), varying from mild to fatal, based on the organ system and severity.